Autolus Therapeutics Provides Business Updates and 2025 Overview
13 janv. 2025 07h00 HE
|
Autolus Therapeutics plc
Autolus announces business updates and an overview of 2025 milestones.
Acute Lymphoblastic Leukemia Market to Surpass USD 4.5 billion with CAGR 7.6% by 2031,TMR Report
05 oct. 2023 07h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The acute lymphoblastic leukemia market was estimated to have acquired US$ 2.2 billion in...
Acute Lymphoblastic Leukemia Market Size to Surpass USD 4.5 billion by 2031, globally, expanding at a CAGR of 7.6%: TMR Report
04 août 2023 10h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The global acute lymphoblastic leukemia market is projected to flourish at a CAGR of 7.6% from 2022 to 2031. As per the report...
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
26 avr. 2023 07h06 HE
|
Autolus Therapeutics plc
- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07 mars 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
NEW LEADING-EDGE TREATMENT FOR LEUKEMIA NOW OFFERED AT NICKLAUS CHILDREN'S HOSPITAL
10 juin 2021 09h54 HE
|
Nicklaus Children's Hospital
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Nicklaus Children's Hospital is one of only a few pediatric hospitals in Florida, and the only one in South Florida, to offer the latest immune cell...
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
05 déc. 2020 15h01 HE
|
Autolus Therapeutics plc
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
16 avr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
07 déc. 2019 14h00 HE
|
Autolus Therapeutics plc
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome Data presented at 61st American Society of Hematology Annual Meeting form...